PIM-1 kinase: a potential biomarker of triple-negative breast cancer
- PMID: 31496730
- PMCID: PMC6690594
- DOI: 10.2147/OTT.S212752
PIM-1 kinase: a potential biomarker of triple-negative breast cancer
Abstract
Triple-negative breast cancer is associated with a poor prognosis, and effective biomarkers for targeted diagnosis and treatment are lacking. The tumorigenicity of the provirus integration site for Moloney murine leukemia virus 1 (PIM-1) gene has been studied for many years. However, its significance in breast cancer remains unclear. In this review we briefly summarized the physiological characteristics and regulation of PIM-1 kinase, and subsequently focused on the role of PIM-1 in tumors, especially breast cancer. Oncogene PIM-1 was found to be upregulated in breast cancer, especially in triple-negative breast cancer. Moreover, it is involved in tumorigenesis and the development of drug resistance, and linked to poor prognosis. A highly selective probe targeting PIM-1 for imaging has emerged, suggesting that PIM-1 may be a potential biomarker for the accurate diagnosis and targeted therapy of triple-negative breast cancer.
Keywords: PIM-1; biomarker; triple-negative breast cancer.
Conflict of interest statement
The authors report no conflict of interest in this work.
Figures
References
-
- Baytel D, Shalom S, Madgar I, Weissenberg R, Don J. The human Pim-2 proto-oncogene and its testicular expression. Biochim Biophys Acta. 1998;1442(2–3):274–285. - PubMed
-
- Domen J, Von Lindern M, Hermans A, Breuer M, Grosveld G, Berns A. Comparison of the human and mouse PIM-1 cDNAs: nucleotide sequence and immunological identification of the in vitro synthesized PIM-1 protein. Oncogene Res. 1987;1(1):103–112. - PubMed
LinkOut - more resources
Full Text Sources
